Moolec Science SA

Moolec Science SA (MLEC) Stock Analysis

$6.800

-0.059 (-0.87%)At close

Loading chart…
High
6.850
Open
6.850
VWAP
6.82
Vol
1.97K
Mkt Cap
40.57M
Low
6.800
Amount
13.39K
EV/EBITDA, TTM
0.00

Moolec Science SA is a science-based food ingredient company. The Company operates an integrated platform encompassing research & development (R&D), manufacturing, and regulatory capabilities that span from molecular design to validation in both fermenter and field environments. It operates across the United States, Europe, and South America. The Company advances its molecular farming programs in crops such as soy and safflower to produce proteins and lipids with animal-like functionality and plant-based cost structures. It is developing a precision fermentation facility in Finland, under the SynBio Powerlabs brand, which will be dedicated to producing target proteins, enzymes, and other biomolecules using optimized microbial and cellular systems. Its product portfolio includes GLASO, PIGGY SOOY, VALORASOY, and MYCOFOOD. Its GLASO, a safflower-derived oil rich in functional lipids, is being used in formulations for small-animal feed.

AI analysis of Moolec Science SA (MLEC)

hold

Moolec Science SA is currently a hold. The stock price is at 6.80, which is down 2.86% over the last five days, but has increased 64.25% year-to-date. However, the RSI is at 40.246, indicating potential weakness, and the gross margin is significantly negative at -25.78%, which raises concerns about profitability. The main risk is the high debt-to-equity ratio of 789.74%, suggesting financial instability.

Valuation Metrics

The current forward P/E ratio for Moolec Science SA (MLEC) is 0.00, compared to its 5-year average forward P/E of -5.95.

Forward P/E

Overvalued
5Y Average P/E
-5.95
Current P/E
0.00
Overvalued
-1.03
Undervalued
-10.86

Forward EV/EBITDA

Fair
5Y Average EV/EBITDA
-6.18
Current EV/EBITDA
0.00
Overvalued
1.12
Undervalued
-13.48

Forward P/S

Fair
5Y Average P/S
9.28
Current P/S
0.57
Overvalued
26.05
Undervalued
-7.49

Alphio AI Price Scenarios for MLEC

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%MLEC

$29.13

Scenario price

B

Base

Base · 50%MLEC

$22.46

Scenario price

B

Bear

Bear · 25%MLEC

$17.06

Scenario price

Events Timeline

2026-07-15 (ET)

10:30:00

Moolec Science SA Trading Halted Due to Volatility Trading Pause

2026-05-14 (ET)

09:20:00

Moolec Science Completes 2026 GLASO Commercial Planting Campaign

2026-04-29 (ET)

09:10:00

Moolec Science Completes First Phase of GLASO1 Industrialization

2026-04-07 (ET)

08:20:00

Moolec Science Successfully Expresses Bovine Myoglobin in Pea Seeds

2026-02-18 (ET)

09:40:00

Moolec Science SA Trading Halted Due to Volatility Trading Pause

News

MLEC FAQ — answered by Alphio AI

Moolec Science SA is a science-based food ingredient company. The Company operates an integrated platform encompassing research & development (R&D), manufacturing, and regulatory capabilities that span from molecular design to validation in both fermenter and field environments. It operates across the United States, Europe, and South America. The Company advances its molecular farming programs in crops such as soy and safflower to produce proteins and lipids with animal-like functionality and plant-based cost structures. It is developing a precision fermentation facility in Finland, under the SynBio Powerlabs brand, which will be dedicated to producing target proteins, enzymes, and other biomolecules using optimized microbial and cellular systems. Its product portfolio includes GLASO, PIGGY SOOY, VALORASOY, and MYCOFOOD. Its GLASO, a safflower-derived oil rich in functional lipids, is being used in formulations for small-animal feed. It operates in the Consumer Non-Cyclicals sector.

Moolec Science SA is currently a hold. The stock price is at 6.80, which is down 2.86% over the last five days, but has increased 64.25% year-to-date. However, the RSI is at 40.246, indicating potential weakness, and the gross margin is significantly negative at -25.78%, which raises concerns about profitability. The main risk is the high debt-to-equity ratio of 789.74%, suggesting financial instability.

This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.

Get Started